{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:48:18Z","timestamp":1789386498880,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2007,9,25]],"date-time":"2007-09-25T00:00:00Z","timestamp":1190678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated tolerability and the efficacy of continuous infusion of apomorphine hydrochloride on involuntary movements and mood disorder in Huntington's disease (HD) patients in a pilot, single center, double\u2010blind, randomized, crossover, and controlled versus placebo study. Nine patients with a molecular diagnosis of HD were screened for response to acute apomorphine injection. Four of them, not ameliorating at the acute test, were discontinued. Five patients, responding to acute apomorphine, received continuous infusion of either apomorphine or placebo for 5 days. After 2 days of washout, the alternative treatment was administered. Primary endpoint measures were scores of the Unified Huntington's Disease Rating Scale (UHDRS \u201cmotor section\u201d) and of the Abnormal Involuntary Movement Scale (AIMS). Secondary endpoint measures were the Hamilton Depression Rating Scale (HAD) score and safety parameters. Both UHDRS and AIMS scores significantly decreased in all patients after apomorphine. The beneficial effect of apomorphine was recorded throughout the 5 treatment days. The HAD score did not change after infusion of either treatment. No serious adverse events were reported by either group during the study. Our results suggest that continuous infusion of apomorphine might be considered for the treatment of involuntary movements in some HD patients. \u00a9 2007 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21718","type":"journal-article","created":{"date-parts":[[2007,9,25]],"date-time":"2007-09-25T16:47:39Z","timestamp":1190738859000},"page":"2359-2364","source":"Crossref","is-referenced-by-count":23,"title":["Short\u2010term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross\u2010over trial"],"prefix":"10.1002","volume":"22","author":[{"given":"Carmine","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Michele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540110037003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.2.358"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.8.848"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.1.84"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.0354e.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.0354f.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(72)90773-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000136818"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1978.00500250064019"},{"key":"e_1_2_6_12_2","series-title":"Apomorphine and other dopaminomimetic","first-page":"145","volume-title":"Clinical Pharmacology","author":"Frattola L","year":"1981"},{"key":"e_1_2_6_13_2","volume-title":"Problems on extrapyramidal dysfunction","author":"Trabucchi M","year":"1976"},{"key":"e_1_2_6_14_2","first-page":"661","volume-title":"Advances in biochemistry and psychopharmacology","author":"Trabucchi M","year":"1977"},{"key":"e_1_2_6_15_2","first-page":"155","article-title":"Effects of DA agonists in Huntington disease hyperkinesia","volume":"3","author":"Caraceni TA","year":"1980","journal-title":"Ital J Neurol Sci"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(74)90319-1"},{"key":"e_1_2_6_17_2","first-page":"645","article-title":"Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man","volume":"16","author":"Corsini GU","year":"1977","journal-title":"Adv Biochem Psychopharmacol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1978.00500250031006"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00735817"},{"key":"e_1_2_6_20_2","first-page":"180","article-title":"Apomorphine injections acutely improve chorea in patients with Huntington's disease","volume":"7","author":"Bentivoglio AR","year":"1992","journal-title":"Mov Disord"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.10.1279"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/mcpr.1993.1034"},{"key":"e_1_2_6_24_2","first-page":"136","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"2","author":"Huntington Study Group","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_6_25_2","volume-title":"ECDEU Assessment manual","author":"AIMS","year":"1976"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00496058"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410260209"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(82)90504-4"},{"key":"e_1_2_6_30_2","first-page":"287","article-title":"Mechanism of thymoleptic drug action studied in the model of apomorphine depression","volume":"10","author":"Tesarova O","year":"1968","journal-title":"Activitas Nerv Sup"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1094329"},{"key":"e_1_2_6_32_2","first-page":"551","article-title":"A contribution to the problem of experimental depression","volume":"8","author":"Tesarova O","year":"1966","journal-title":"Activitas Nerv Sup"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.38.7.722"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000117691"},{"key":"e_1_2_6_35_2","first-page":"113","article-title":"Apomorphine, pimozide, L\u2010Dopa and the probenecid test in Huntington's chorea","volume":"76","author":"Lal S","year":"1973","journal-title":"Psychiatria Neurologia Neurochirurgia"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21718","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:25:22Z","timestamp":1760963122000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,15]]},"references-count":34,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2007,12,15]]}},"alternative-id":["10.1002\/mds.21718"],"URL":"https:\/\/doi.org\/10.1002\/mds.21718","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,15]]}}}